Announcements Trials
Browse Landscape

Status

Approved for marketing 2No longer available 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 94Observational 20Expanded_access 3

Sponsor

Cancer Type

NET 3Endocrine 3

Conditions

Carcinoma, Non-Small-Cell Lung 32Multiple Myeloma 26Neoplasms 25Recurrence 23Melanoma 19Leukemia, Myeloid, Acute 16Breast Neoplasms 15Prostatic Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Sarcoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lung Neoplasms 9Ovarian Neoplasms 8Lymphoma 8Glioma 8Colorectal Neoplasms 8Small Cell Lung Carcinoma 7Lymphoma, Large B-Cell, Diffuse 7Carcinoma, Renal Cell 7Lymphoma, Non-Hodgkin 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Gastrointestinal Stromal Tumors 6Cholangiocarcinoma 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 5Neoplasm Metastasis 5Leukemia, Lymphocytic, Chronic, B-Cell 5Thyroid Neoplasms 4Lymphoma, Mantle-Cell 4

Interventions

surufatinib 1lutetium Lu 177 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × Neuroendocrine Tumors × Clear all
NCT04814732 2024-04-12

Expanded Access Program of Surufatinib

Hutchmed

No longer available
EndocrineNET

Neuroendocrine Tumors

NCT04334837 2020-10-09

Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)

Curium US LLC

Approved for marketing
EndocrineNET

Neuroendocrine Tumors

NCT02705313 2018-04-09

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

Advanced Accelerator Applications

Approved for marketing
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡